Home › Funds › Vestal Point Capital, LP › MLTX
Vestal Point Capital, LP position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
Vestal Point Capital, LP reported holding 525,000 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$6.1M, representing 0.16% of its reported portfolio and ranking #48 among its reported holdings. Vestal Point Capital, LP has disclosed MLTX holdings in 3 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's MLTX position evolved
Vestal Point Capital, LP first disclosed a stake in MLTX in Q1 2025 at 200,000 shares (US$7.8M). The position peaked in Q2 2025 at 550,000 shares, worth US$26.0M. Across 3 filings, Vestal Point Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 525,000 shares valued at US$6.1M. Notable position changes include a 175% increase in Q2 2025 (shares fell 85% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 200.00K | $7.81M | New |
| Q2 2025 | 550.00K | $25.96M | Add |
| Q3 2026 | 525.00K | $6.14M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 19 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$187.2M), Deep Track Capital, LP (US$94.8M), Cormorant Asset Management, LP (US$33.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $187.22M · Q3 2026
- Deep Track Capital, LP 8.11M sh · $94.83M · Q3 2026
- Cormorant Asset Management, LP 2.86M sh · $33.41M · Q3 2026
- Weiss Asset Management LP 2.34M sh · $27.39M · Q3 2026
- Trails Edge Capital Partners, LP 1.68M sh · $19.66M · Q3 2026
- Logos Global Management LP 1.50M sh · $17.55M · Q3 2026
- Vivo Capital, LLC 1.40M sh · $16.38M · Q3 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held MLTX?
Vestal Point Capital, LP has disclosed MLTX holdings in 3 of the last 7 reported quarters, going back to Q1 2025.
What is Vestal Point Capital, LP's current position in MLTX?
As of Q3 2026, Vestal Point Capital, LP holds 525.00K shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $6.14M, representing 0.16% of its reported portfolio and ranking #48.
Has Vestal Point Capital, LP been buying or selling MLTX?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP newly opened its position in MLTX. The position peaked in Q2 2025 at 550.00K shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Cormorant Asset Management, LP, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.